Clinical Trial to Evaluate the Efficacy and Safety of DWKH

Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWKH

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05683951

Enrollment

186

Registered

2023-01-13

Start date

2021-11-26

Completion date

2022-12-16

Last updated

2023-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Infection

Brief summary

Randomized, Double-blind, Parellel, Multicenter, Active-controlled

Interventions

DRUGDWKH

Administration of DWKH three times daily

DRUGDWKH-R

Administration of DWKH-R three times daily

DRUGPlacebo

Administration of Placebo three times daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Male and female aged between 19 and 80. * Patients whose BSS score is over 5.

Exclusion criteria

* Patients allergic to any ingredients of the study drugs. * Moderate liver disease (ALT or AST \> UNLx3). * Moderate lung disease. * Uncontrolled HTN. * Uncontrolled DM. * Uncontrolled thyroidism. * Patients who is needed antibiotics during the study period. * In the case of women, pregnant(Urine-HCG positive) or lactating women.

Design outcomes

Primary

Measure	Time frame	Description
Bronchitis severity score (BSS)	0,4,7 days	Difference of the BSS score (0 to 4, higher score means more severe)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026